Drug intelligence / Profile preview

XLNT-2

Development stage: Preclinical
Lead developer: NAMI
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

XLNT-2 is a radiopharmaceutical candidate being developed by NAMI Therapeutics for the treatment of advanced and resistant malignancies. It is part of the company's XLNT series of radiopharmaceuticals, which are designed to address multiple cancers characterized by resistance and metastasis. XLNT-2 is specifically being investigated for its potential in treating liver cancer and resistant cancers that have developed peritoneal metastasis. As of early 2024, the program is in the pre-clinical stage of development, focusing on delivering targeted radiation therapy to tumor sites while minimizing systemic exposure.

Beyond the preview

Go deeper on XLNT-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XLNT-2.

Explore the full profile